|
Market Closed -
NYSE
01:30:00 08/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2.710 USD | -0.73% |
|
-1.81% | +50.56% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 218.3 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 50.84% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 218.3 | 218.3 | 218.3 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 50.84% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.3x | 54.2x | 136x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.3x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.66x | 3.28x | 3.17x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.66x | 3.28x | 3.17x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.67x | 84.4x | 193x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 82.16 | 66.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 22.59 | 2.588 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 19.63 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.710 | 2.710 | 2.710 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/03/22 | 27/02/23 | 14/03/24 | 17/03/25 | 18/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.29x | - | - | - | 22Cr | |
| 33.76x | 12.26x | 24.76x | 0.58% | 1,06000Cr | |
| 28.75x | 6.35x | 18.21x | 2.07% | 62TCr | |
| 34.38x | 7.99x | 16.52x | 2.56% | 48TCr | |
| 103.88x | 5.82x | 24.82x | 2.39% | 35TCr | |
| 19.43x | 4.75x | 11.8x | 2.78% | 35TCr | |
| 20.28x | 5.28x | 13.08x | 3.01% | 27TCr | |
| 20.79x | 4.27x | 12.2x | 2.08% | 25TCr | |
| 26.09x | 6.8x | 12.11x | 2.44% | 22TCr | |
| -44.42x | 6.54x | 25.48x | 2.24% | 18TCr | |
| Average | 25.42x | 6.67x | 17.66x | 2.24% | 37.88TCr | |
| Weighted average by Cap. | 32.19x | 7.84x | 19.08x | 1.91% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
